The discovery and status of sibutramine as an anti-obesity drug

This publication has 50 references indexed in Scilit:

• Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid
  Neuropharmacology, 2000
• Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
  Neuropharmacology, 2000
• Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications
  International Journal of Obesity, 2000
• Absence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine
  Obesity Research, 1999
• Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
  The American Journal of Medicine, 1999
• Valvular Heart Disease Associated with Dexfenfluramine
  New England Journal of Medicine, 1997
• [3H]Nisoxetine—A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments
  Neuropharmacology, 1996
• D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
• [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments
  Neuropharmacology, 1993
• The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988